5 May 2022
Press Releases
Small Pharma to Participate in the PSYCH Symposium: London May 11, 2022
May 5th, 2022 – Small Pharma will participate in the PSYCH Symposium: London 2022 –…
Resources
Check out the latest news, press releases, events and insights or delve into all the content on specific topic areas such as DMT.
27 April 2022
Press Releases
Small Pharma To Present at the KCSA Psychedelics Virtual Investor Conference on April 28, 2022
April 27, 2022 – Small Pharma Inc. will present live at the KCSA Psychedelics Virtual…
20 April 2022
Insights
A brief history of DMT
DMT, short for N, N-Dimethyltryptamine, is a naturally-occurring, fast-acting psychoactive molecule. Also described as the…
5 April 2022
News
5 Most Important Psychedelic Clinical Trials in 2022
James Halifax, Psychedelic Spotlight writer and their resident psychedelic investor, recently covered his 5 most…
28 March 2022
News
DMT-Assisted Therapy May Address Root Cause of Major Depression
Gail Dutton of BioSpace.com, a leading online biotechnology source for breaking industry news and expert analysis,…
22 March 2022
News
Small Pharma CEO Peter Rand & CMSO Dr Carol Routledge at the 34th Annual Roth Conference
View Small Pharma’s Fireside Chat Webcast from the 34th Annual Roth Conference Monday, March 14 at 3:30…
10 March 2022
Press Releases
Small Pharma Expands Potential of Commercial Portfolio with DMT-based Psychedelic Assets
Lead DMT-assisted therapy candidate SPL026’s clinical development program strengthened with the addition of two clinical…
9 March 2022
Events
Small Pharma to participate in the 34th Annual Roth Conference
Presentation to be webcast on Monday, March 14 at 3:30 – 3:55PM/PT Small Pharma is…
1 March 2022
Events
PSYCH Symposium London, May 11, 2022
Small Pharma is pleased to announce its attendance at the PSYCH SYMPOSIUM: London 2022. Guest…
22 February 2022
Press Releases
World’s First clinical trial for DMT-assisted therapy in Major Depressive Disorder Shows Consistent Quality of Psychedelic Response in Phase I
In the Phase I clinical trial, participants were administered SPL026 and underwent a 20-minute psychedelic…
TSXV:DMT
OTCQB:DMTTF
About Small Pharma
We’re a mental health drug development company that’s accelerating the development of fast acting antidepressant treatments using DMT based therapies. We’re dedicated to making a difference.
With a focus on innovative approaches and committed to challenging the status quo, we’re targeting the root causes of depression and hoping to unlock the minds of millions.